Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading Into 2026NEWARK, DE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- ...

Hims & Hers Health, Inc. is rated a Buy with strong subscriber growth and rising revenue per subscriber. Learn more about ...

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers ...

Examination of transdermal berberine delivery, GLP-1 pathway terminology in supplement marketing, and consumer evaluation ...

After arresting Venezuela's president, Trump and top U.S. officials warned other countries could be the targets of American ...

Triazoles are privileged five-membered aromatic heterocycles featuring three consecutive nitrogen atoms, and have emerged as versatile scaffolds in ...

How long would you need to jab yourself...and contend with the cost? Two MDs specializing in weight loss and endocrinology ...

Lately, those of us who want help losing weight have more options than ever before. So what exactly is the best weight loss ...

The list includes any case which Richland Source has published as an indictment, stories which first began publishing here in February 2024.

Novamigra Therapeutics secures ~€3 million funding to advance first-in-human Phase 1 study of its migraine prophylaxis ...

It’s not often I agree with George Rebane’s analysis of world events, but during his fairly innumerate rant about the economics of battling climate change, he did strike a ...

Why LifeMD's price target story is shifting LifeMD's fair value estimate sits at US$9.25 per share, with only minor tweaks to key inputs such as the discount rate and revenue trend, which are now ...